REG - Celadon Pharma. PLC - Equity Fundraise and Update on Financial Position

Celadon PharmaceuticalsAnnouncement

11/09/2024 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240911:nRSK6612Da&default-theme=true

RNS Number : 6612D  Celadon Pharmaceuticals PLC  11 September 2024

Celadon Pharmaceuticals Plc

("Celadon", the "Group" or the "Company")

Equity Fundraise and Update on Financial Position

London, 11 September 2024 - Celadon Pharmaceuticals Plc (AIM: CEL), a UK-based
pharmaceutical company focused on the development, production and sale of
breakthrough cannabis-based medicines, is pleased to announce that it has
raised £1.05m (the "Fundraise") through a placing of 2,625,000 new ordinary
shares of 1 pence each in the Company ("New Ordinary Shares").  The New
Ordinary Shares will be issued at a price of 40 pence per share (the
"Fundraise Price"), which represents a discount of approximately 23.8 per cent
to the previous day closing price of 52.5 pence per share on 10 September
2024, being the last practicable date prior to the publication of this
announcement.  The Company also wishes to provide an update on its financial
position.

Application will be made for admission of the New Ordinary Shares to trading
on AIM.  It is expected that admission will occur on or around 17 September
2024, with cash settlement on 18 September 2024.  The Company's pre-existing
authority to allot ordinary shares granted at the 2024 AGM is sufficient to
allot the New Ordinary Shares.

Global Investment Strategy UK Limited undertook the placing for which they
will receive a cash fee based on the amount raised and warrants over 131,250
new ordinary shares, which can be exercised until 10 September 2027, with an
exercise price of 40 pence per share.

Update on Financial Position

On 23 August 2024, the Company provided an update on its financial position.
In that update the Company advised that it had experienced delays in expected
funding (the "Delayed Funding") from a historical equity fundraising round,
announced on 10 May 2024, and following the submission of a draw down request
on its Committed Credit Facility.

The Company continues to be in dialogue with the equity subscriber (the
"Subscriber") and lender including through the Fundraise process and both have
re-confirmed their intentions to pay the balances due.  The Company will make
further announcements when the expected funds are received.

The Board also wishes to advise that the Group continues to be in discussion
with a small number of potential institutional lenders about entering into
substantial longer term debt facilities that would allow the Committed Credit
Facility to be refinanced. These discussions however have yet to advance
materially since the Company first disclosed them in an RNS on 12 August 2024.

Current Cash Position

The Company continues to manage its cash position and creditors tightly, and
this has been exacerbated by the Delayed Funding. The Delayed Funding is a
primary reason for the Company proceeding with the Equity Fundraise as the
Company has sought to have sufficient cash for its short term cash
requirements.

The Company's cash position as at 10 September 2024 was £48k, meaning that
the cash resources available to the Company upon receipt of the Fundraise
proceeds will be £1,046k. Based on the current forecasts of the Company, the
cash resources available to the Company are expected to finance the working
capital requirements of the Company through to December 2024, with the Company
continuing to manage its cash position and assuming careful creditor
management. This funding timeframe is expected to increase once the remaining
proceeds of the subscription and the funds due under the draw down are
received. While the Directors remain confident of receiving the funds from the
Delayed Funding, and there is a legal requirement on both parties to make
payment, the Board notes the significantly delayed timeframe of payment which
raises uncertainty that the funds will be received at all.

The Company intends to publish its unaudited interim results for the six
months ended 30 June 2024 before the end of September 2024. A further update
on the Company's working capital position will be provided within these
results.

James Short, Chief Executive Officer of Celadon, commented:

"Celadon is grateful to the investors who have participated in the
Fundraising, and to the Subscriber and lender for their re-confirmed
commitments to the Company. The Group's ongoing conversations with alternative
potential lenders continue with a view to securing the long-term future for
the business.

 

Following this morning's announcement of the Group's strategic collaboration
with Valeos Pharma A/S, the Fundraise and ongoing funding discussions give the
Group confidence in the long term value of the Group."

 

 

Enquiries:

 Celadon Pharmaceuticals Plc
 James Short                                                                                    Via Sodali & Co

 Jonathan Turner

 Canaccord Genuity Limited (Nominated Adviser and Broker)
 Bobbie Hilliam / Andrew Potts                                                                  +44 (0)20 7523 8000

 Global Investment Strategy UK Limited (Joint Broker)                                           +44 (0)20 7048 9400

 James Sheehan

 Sodali & Co
 Elly Williamson / Sam Austrums / Nick Johnson                                                  +44 (0)20 7250 1446

 

About Celadon Pharmaceuticals Plc

 

Celadon Pharmaceuticals Plc is a UK-based pharmaceutical company focused on
the development, production and sale of breakthrough cannabis-based medicines.
Its primary focus is on improving quality of life for chronic pain sufferers,
as well as exploring the potential of cannabis-based medicines for other
conditions such as autism. Its 100,000 sq. ft UK facility is EU-GMP approved
and comprises indoor hydroponic cultivation, proprietary GMP extraction and an
analytical and R&D laboratory. Celadon's Home Office licence allows for
the commercial supply of its pharmaceutical-grade cannabis product. The Group
owns an approved clinical trial using cannabis-based medicinal products to
treat chronic pain in the UK. Celadon also has a minority interest in
early-stage biopharma Kingdom Therapeutics, which is developing a licensed
cannabinoid medicine to treat children with Autism Spectrum Disorder.

 

For further information please visit our website www.celadonpharma.com
(http://www.celadonpharma.com)

 

This announcement contains inside information for the purposes of article 7 of
the Market Abuse Regulation (EU) 596/2014 as amended by regulation 11 of the
Market Abuse (Amendment) (EU Exit) Regulations 2019/310. With the publication
of this announcement, this information is now considered to be in the public
domain.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCGPUCUBUPCPGU